The quarterly release indiates the company is getting through to profitability and cashflow sustainability. Management team seems to have done a good job across the board – cash, price, volume, renegotiations, cost control, efficiency, etc. They also understand the challenge now is to drive the software sales and revenue much faster in 2026. Despite the relatively small software development spend (circa AUD800K) they seem to be getting a very good bang for the buck with a lot of new releases in the quarter. The radiology business has achieved a solid return to positive contribution in the second half.
Have other thoughts on ImExHS?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
The user Wobbegong holds no position in ASX:IME. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.